Scientists at the University of British Columbia have pioneered a magnetic retinal implant that can supply a regulated and on-demand release of drugs to treat blindness from diabetic retinopathy.
Belgium-based biopharmaceutical company, ThromboGenics, has signed a ten-year supply agreement with MSD Biologics, to produce microplasmin for the treatment of retinal disorders.